NYSE: ENOV · Medical Devices
Enovis (ENOV) fair value: undervalued or overvalued?
As of 3 Oct 2026, Faircurve's model values Enovis (ENOV) at $23.09 a share. The stock last closed at $17.77, which puts the model's fair value 29.9% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 2 Oct 2026. Enovis Corporation.
Faircurve Insights · 3 Oct 2026
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. It operates in Healthcare and Medical Devices.
Faircurve's model valued the company on 3 Oct 2026, giving a fair value of $23.09 a share. This is the midpoint of 2,000 simulations. The previous run on 26 Sep 2026 gave $25.00, meaning the fair value moved -7.6%. The calibrated range over 63 trading days is $19.26 to $27.99, built from the fair value since there is no live options data for the stock, and calibrated weekly against realised prices. Ranges built this way held the price 60% of the time at this horizon, across 4,809 past valuations refreshed on 3 Oct 2026. The model's evidence grade is Medium.
The company's overall quality score is 56 out of 100 against comparable companies. Its quality factors include Profitability 46, Earnings quality 100, Growth quality 47, Capital discipline 58, Balance sheet 70, and Stability 0. The model compares it with Integra LifeSciences Holdings Corporation, Artivion, Inc., Tandem Diabetes Care, Inc., Cytek Biosciences, Inc., and UFP Technologies, Inc. Around its last 8 earnings reports, the stock moved a median of 10.5%, ignoring direction.
Written from the figures on this page for the 3 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give ENOV?
The calibrated range for ENOV over 63 trading days is $19.26 to $27.99. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,809 past valuations, refreshed 3 Oct 2026). Ranges built this way held the price 60% of the time at this horizon.
The price is below this range. For names with fair value 15 to 30% above price, the calibrated range has held the price 50% of the time over 63 trading days, and 48% ended below it; the typical move was +3.7%.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $13.65 to $33.56. In 68% of the simulations the fair value came out above the price the model ran on.
How does ENOV score on business quality?
Enovis's overall quality score is 56 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 46 | 3.3%ROIC | -0.8% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 47 | 6.7%Revenue growth, trailing | 9.3% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 58 | 0.1%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 70 | -1.89xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 0 | 16.7 ptsEBITDA margin downside volatility, 5y | 8.9 pts |
How does ENOV compare with similar companies?
The companies in medical devices closest to Enovis in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| IART Integra LifeSciences Holdings Corporation | $12.68 | $15.96 | +25.9% | Undervalued |
| AORT Artivion, Inc. | $22.31 | $26.81 | +20.2% | Undervalued |
| TNDM Tandem Diabetes Care, Inc. | $16.50 | $20.57 | +24.7% | Undervalued |
| AHCO AdaptHealth Corp. | $5.60 | $5.55 | -0.9% | Low evidence grade |
| CTKB Cytek Biosciences, Inc. | $5.87 | $7.27 | +23.9% | Undervalued |
| CNMD CONMED Corporation | $46.32 | $57.63 | +24.4% | Low evidence grade |
| INSP Inspire Medical Systems, Inc. | $69.97 | $70.18 | +0.3% | Low evidence grade |
| UFPT UFP Technologies, Inc. | $300.70 | $278.76 | -7.3% | Fairly valued |
When does ENOV report earnings, and how has the stock reacted?
Enovis's next earnings report is scheduled for 5 Nov 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 22.5% in either direction through the nearest expiry, about 48 days out, a window that includes the report. That is the size the market is pricing, not a direction.
How ENOV moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 10.5%.
| Report date | Two session move |
|---|---|
| 6 Aug 2026 | -11.8% |
| 7 May 2026 | +6.7% |
| 26 Feb 2026 | +14.1% |
| 6 Nov 2025 | -10.9% |
| 7 Aug 2025 | +10.4% |
| 8 May 2025 | -10.4% |
| 26 Feb 2025 | -9.5% |
| 6 Nov 2024 | +10.5% |
Enovis at a glance
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices.
- Market value
- $1.0B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $2.4B
- Consensus revenue growth, next fiscal year
- +4.1%
- Analysts with estimates
- 6
- Beta to the US market
- 1.23
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Enovis on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 26 Sep 2026 the model's fair value for ENOV was $25.00. As of 3 Oct 2026 it is $23.09, a change of -7.6%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Enovis's valuation
Is Enovis stock undervalued or overvalued?
On Faircurve's model, ENOV reads as Undervalued as of 3 Oct 2026. The model's fair value is $23.09 a share against a last close of $17.77, a gap of +29.9%.
What is ENOV's fair value?
$23.09 a share as of 3 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $13.65 to $33.56.
What price range does the model give ENOV?
$19.26 to $27.99 over 63 trading days. Ranges built this way held the price 60% of the time across 4,809 past valuations, refreshed 3 Oct 2026.
When does Enovis report earnings next?
The next report is scheduled for 5 Nov 2026. Companies can move their dates.
How much has ENOV moved on past earnings reports?
Across its last 8 reports the median two session move was 10.5%, ignoring direction. The largest was +14.1% around the report of 26 Feb 2026.
How confident is the model in this valuation?
The model's evidence grade for ENOV is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.